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result in long lists of ‘‘signiﬁcant genes.’’ One way to gain insight into the signiﬁcance of altered expres-
sion levels is to determine whether Gene Ontology (GO) terms associated with a particular biological pro-
cess, molecular function, or cellular component are over- or under-represented in the set of genes
deemed signiﬁcant. This process, referred to as enrichment analysis, proﬁles a gene set, and is widely
used to make sense of the results of high-throughput experiments. Our goal is to develop and apply gen-
eral enrichment analysis methods to proﬁle other sets of interest, such as patient cohorts from the elec-
tronic medical record, using a variety of ontologies including SNOMED CT, MedDRA, RxNorm, and others.
Although it is possible to perform enrichment analysis using ontologies other than the GO, a key pre-
requisite is the availability of a background set of annotations to enable the enrichment calculation. In the
case of the GO, this background set is provided by the Gene Ontology Annotations. In the current work,
we describe: (i) a general method that uses hand-curated GO annotations as a starting point for creating
background datasets for enrichment analysis using other ontologies; and (ii) a gene-disease background
annotation set – that enables disease-based enrichment – to demonstrate feasibility of our method.
 2011 Elsevier Inc. All rights reserved.1. Introduction
One way to gain insight into the signiﬁcance of a particular set
of genes is to determine whether functional terms that are associ-
ated with each gene are over- or under-represented in the set of
genes deemed signiﬁcant. This process, referred to as enrichment
analysis, proﬁles a gene set, and is widely used to make sense of
the results of high-throughput experiments such as gene-
expression assays. The canonical example of enrichment analysis
is in the interpretation of a list of differentially expressed genes
in some condition. The usual approach is to perform enrichment
analysis with the Gene Ontology (GO). We can aggregate the anno-
tating GO concepts associated with a particular biological process,
molecular function, or cellular component for each gene in this list,
and arrive at a proﬁle of the biological processes or mechanisms
affected by the condition under study [1]. There are currently over
400 publications on methods and tools for GO-based enrichment,
but (to the best of our knowledge) only a single other tool, Genes2-
Mesh, uses something besides the GO (i.e., the Medical Subject
Headings or MeSH), to calculate enrichment [2]. Our goal is to
develop and apply general enrichment analysis methods to proﬁle
other sets of interest, such as patient cohorts from the electronicll rights reserved.
u).medical record, using a variety of ontologies including SNOMED
CT, MedDRA, RxNorm, and others.
While the GO has been the principal target for enrichment anal-
ysis, we can carry out the same sort of proﬁling using any ontology
available in the biomedical domain. Tirrell et al. have developed a
prototype tool [3] called RANSUM – Rich Annotation Summarizer –
that performs generalized enrichment analysis using any ontology
from the National Center for Biomedical Ontology’s (NCBO) online
repository of public ontologies called BioPortal [4].
By using a disease ontology in such analysis, we can enable
translational questions: just as scientists can ask which biological
process is over-represented in a set of differentially expressed
genes, they can also ask which disease (or class of diseases) is
over-represented in a set of genes or proteins that share a common
characteristic. For example, by annotating known protein muta-
tions with disease terms, Mort et al. identiﬁed a class of dis-
eases—blood coagulation disorders—that are associated with a
signiﬁcant depletion in substitutions at O-linked glycosylation
sites [5]. Similarly, by identifying other disease associations for
the genes involved in a certain disease of interest we can gain in-
sight into how the causation of seemingly unrelated diseases might
be related, e.g., Werner’s syndrome, Cockayne syndrome, Burkitt’s
lymphoma, and Rothmund–Thomson Syndrome [6–9]. We can also
apply the enrichment analysis methodology to other sets of inter-
est—such as patient cohorts. For example, enrichment analysis
might detect speciﬁc co-morbidities that have an increased
S32 P. LePendu et al. / Journal of Biomedical Informatics 44 (2011) S31–S38incidence in rheumatoid arthritis patients—a topic of recent dis-
cussion in the literature and considered essential to provide high
quality care [10–12]. Enrichment analysis to identify common
pairs of terms of different semantic types can identify combina-
tions of drug classes and co-morbidities, or test risk-factors and
co-morbidities that are common in this population; in fact Petri
et al. recently identiﬁed co-morbidities in rheumatoid arthritis pa-
tients using relative risk analysis (which shares similarities with
enrichment analysis) calculated from ICD9 codes in a retrospective
cohort study using medical claims data [13].
Note that enrichment analysis as discussed in this paper and as
performed by the majority of the tools listed online1 by the GO
Consortium is conceptually different from the similarly named Gene
Set Enrichment Analysis (GSEA) method [20], where groups of genes
that are known to share common biological function, chromosomal
location, or regulation are tested collectively for signiﬁcant differ-
ence in expression between two phenotypic conditions such as
tumors that are sensitive versus resistant to a drug. The goal of GSEA
is to determine whether members of a gene set S—as deﬁned by
common biological function, chromosomal location, or regulation—
tend to occur toward the top (or bottom) of the list L (comprised
of genes showing the largest difference in expression between the
two phenotypic classes), in which case the gene set is deemed to
be correlated with the phenotypic condition under study.
One key aspect of calculating functional enrichment (such as
GO term enrichment) is the choice of a reference-term frequency
since the calculation compares the term frequencies in the annota-
tions of a set of interest against the annotations of a reference set.
It is not clear what the appropriate reference-term frequency
should be when calculating enrichment of ontology terms for
which a ‘‘background set’’ is not deﬁned. For example, in the case
of Gene Ontology annotations, the background set is usually the
GO annotations of the set of genes on which the data were col-
lected on a microarray or the GO annotations of all the genes
known in the genome for the species on which the data were col-
lected. A natural background set is not available, however, when
calculating enrichment using disease ontologies because these
ontologies have not been used for manual annotation in a way
the Gene Ontology has been used.
For situations lacking an obvious background set, there are two
main options: As Tirrell et al. note, we can use the frequency of
ontology terms in a large corpus, such as the NCBO Resource Index
[14,15], MEDLINE abstracts or on Web pages indexed by Internet
search engines such as Google. Using such an ‘‘off the shelf’’ refer-
ence set has the drawback of not being representative of the
speciﬁc set of interest being analyzed, for example, in the case of
analyzing patient cohorts. One alternative is to construct a refer-
ence annotation set using automated methods.
Our approach is to construct a reference set programmatically
using manually created GO annotations as a starting point. We
speciﬁcally choose GO annotations because they provide a reliable
foundation—highly trained curators associate GO terms to gene
products, based on exhaustive literature review. Building upon this
foundation, we demonstrate how, with the availability of tools for
automated annotation with terms from disease ontologies, it is
possible to create reference annotation sets for enrichment analy-
sis using ontologies other than the GO—for example, the Human
Disease Ontology (DO).
Basically, a manually curated GO annotation associates a gene
product with a PubMed article with high accuracy. We hypothesize
that if a disease term is mentioned in the abstract of the article
based on which a GO annotation is created for a gene product, then
that disease term is likely to be associated with that gene product;1 http://geneontology.org/GO.tools_by_type.term_enrichment.shtmland we can associate relevant disease terms to those gene products
by analyzing the text in the title and abstract of the article. Unlike
GO terms, which actually appear in the text with low frequency
(see Section 4.1), or gene identiﬁers, which are ambiguous, disease
terms are highly amenable to automated, term extraction tech-
niques [16]. Therefore, using tools that recognize mentions of
ontology terms in user submitted text such as the NCBO annotator
[17], we can automatically recognize occurrences of disease terms
from the DO in a given corpus of text; the key is to identify a reli-
able text source to recognize disease terms from, to associate with
genes and gene products.
Therefore, by starting with curated gene associations we can
reliably obtain gene-disease associations from biomedical litera-
ture. Researchers can then use these associations to automatically
generate a gene-disease association ﬁle as a background set (or ref-
erence set) for disease-speciﬁc enrichment analysis. Moreover,
researchers can reuse our method to examine annotations along
other dimensions. For example, researchers can use the Pathway
ontology to generate gene-pathway associations, or fragments of
SNOMED CT to generate gene-anatomy associations.
What differentiates our method from other approaches that
infer gene-disease associations—such as co-occurrence analysis
or syntactic–semantic relationship extraction techniques, which
might require difﬁcult to obtain training sets for ﬁnding gene-
disease associations [18]—is the reuse of publicly available GO
annotations as a basis for identifying reliable gene-publication
records that serve as the foundation for generating automated
annotations. Furthermore, unlike dictionary-based approaches
[18], we assign public ontology term identiﬁers (e.g., DO identiﬁers
or DOIDs) during the annotation process, which can be reasoned
over to aggregate, ﬁlter, and cross-reference associated disease
terms. In a similar approach to ours, Osborne et al. argue that anno-
tating GeneRIF descriptions with DO terms to infer gene-disease
relationships offers greater signal-to-noise than mining 20 million
MEDLINE articles directly, given the nature of curated GeneRIF
descriptions [16]. In the results, we quantify the increased cover-
age of our approach.
In summary, our main contributions are: (i) a general method,
which uses hand-curated GO annotations as a starting point for
creating background datasets for enrichment analysis using other
ontologies; and (ii) a gene-disease background annotation set—
that enables disease-based enrichment analysis—to demonstrate
feasibility of our method.2. Methods
Fig. 1 summarizes our method. First, we start with GO annota-
tions, which provide the PubMed identiﬁers of papers based on
which gene products are associated with GO terms by a curator.
The annotations essentially give us a link between gene identiﬁers
and PubMed articles and only those PubMed articles that were
deemed to be relevant for the process of creating GO annotations.
Next, we recognize terms from an ontology of interest (e.g., DO) in
the title and abstracts of those articles. Finally, we associate the
recognized ontology terms with the gene identiﬁers to which the
article analyzed was associated.2.1. Obtaining gene-publication associations
We download GO annotation ﬁles2 for human gene products
from geneontology.org. These ﬁles are tab-delimited text ﬁles that
contain, among other things, a list of gene identiﬁers, associated2 http://www.geneontology.org/GO.downloads.annotations.shtml
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Annotator service. Terms associations can be expanded based on inferred hierarchical relationships. Finally, the gene-to-article associations are linked with the curated
article-to-term associations to obtain a list of gene-to-term associations. The resulting term frequencies provide a background set for enrichment analysis.
Term A
Term B
Term C
Term D
Term E
Term F
Ontology Term
Gene
(Patient, etc.)
M=11
N=3
Set of Interest
Term B: enriched!
n=3, m=4
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basis of which the GO annotation was created.
We remove all electronically inferred annotations (IEA) from
the ﬁle because they are less reliable. We also remove all qualiﬁed
annotations, such as negated (NOT) ones. As a result, we obtain a
list of publications and the genes they describe, gene-publication
tuples. In the next phase, we process the publications to obtain
publication–disease tuples.
2.2. Parsing article titles and text
Using the PubMed identiﬁers obtained from the GO annotation
ﬁles, we fetch each article’s title and abstract using the National
Library of Medicine eUtils.3 We save each article’s title and abstract
as a ﬁle and process it using the disease ontology with the Annotator
service.
2.3. Annotating text using terms from the Human Disease Ontology
For each PubMed article, we use the NCBO Annotator Web-
service4 to identify mentions of disease terms from the DO in the
text. We conﬁgure the service to ﬁnd the longest, whole-word
matches for term labels and synonyms from the DO. Speciﬁcally,
we set the following Annotator Web-service parameters for our
study: wholeWordOnly = true, scored = true, ontologiesToExpand =
42986, withDefaultStopWords = true, levelMax = 0. The Human Dis-
ease Ontology is indicated by the BioPortal version id 42986. Other
details on the Web-service parameters are documented in the online
user guide.
For every matched term, we acquire the appropriate disease
concept identiﬁer resulting in a list of publication-to-disease con-
cept tuples. In other words, the annotation process performs con-
cept normalization. Having the concept identiﬁer, we can invoke
hierarchy and mapping Web-services from BioPortal to expand
the associations to include parent or related terms, if desired. Mul-
tiple matches of a term within the text, and relative word ordering
are not taken into account. Also, for this study, levelMax = 0, means
that we do not expand terms based on hierarchies.
2.4. Obtaining the gene-disease background annotation set
Once we have the publication–disease tuples, we connect them
to the gene-publication tuples resulting in gene-disease associa-3 http://eutils.ncbi.nlm.nih.gov/
4 http://www.bioontology.org/wiki/index.php/Annotator_User_Guidetions for 7316 human genes. Finally, we compute the disease con-
cept frequencies from the gene-disease background annotation set
by simply counting the number of distinct genes associated with
each disease over all documents in the corpus. To compute the
background frequency for each disease concept X, we add up the
gene occurrence counts for disease concept X across all publica-
tions. We return this number (m) as well as the total number of
genes in the background annotation set (M = 7316). The fraction
m/M then represents the background frequency of the disease con-
cept X in the annotated corpus. Using this frequency we can com-
pute signiﬁcant comparative over- or under-representation in an
input dataset. See Fig. 2 for an illustration.2.5. Calculating the gene-disease enrichment value for a set of interest
Using 261 genes known to be associated with aging (obtained
from GenAge, see Section 3) as an example set of interest, we
re-compute the frequency for each concept X by summing the gene
occurrences for disease concept X this time only if the gene ap-
pears within this subset. We return this number (n) as well as
the total number of genes in the set of interest (N = 261). The frac-
tion n/N then represents the observed frequency of the concept X
for the set of interest. See Fig. 2 for an illustration.
Finally, we assess how ‘‘surprising’’ it is to ﬁnd n, givenm,M and
N by calculating the probability of observing a speciﬁc value given
the background distribution. We use a simple binomial model to(i.e., genes, patients, etc.). The background set depicted has M = 11 entities. The set
of interest has N = 3 entities. Term B has three links to the set of interest (n = 3) and
four links to the background set (m = 4). For p-values under 0.05, the binomial test
shows that Term B is enriched for n/N versus m/M.
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ing a gene annotated with a disease concept is ﬁxed and is equal to
the proportion of genes annotated with that term in the reference
set. Such an approximation is quite reasonable for large reference
sets (e.g., the whole genome) because the probability of selecting
a gene annotated with the term into the set of interest does not
change signiﬁcantly after each selection. An alternative for smaller
reference sets would be to use a hypergeometric distribution,
which models the selection process without replacement. The
trade-offs between using the binomial versus the hypergeometric
distribution for gene-centric enrichment tests are studied by
McLean et al. [19].2.6. Evaluation
In order to validate our background annotation set, we evaluate
our gene-disease association dataset in several ways. First, we
manually verify a handful of well-known genes, such as TP53, for
known associations with diseases. Next, we examine a set of genes
related speciﬁcally to aging from the GenAge database [23] for
their coherence in terms of the assigned disease annotations. Final-
ly, we perform disease-based enrichment analysis on the aging
gene set using our newly created background set.3. Results
The GO annotation ﬁles for homo sapiens reference 44,103 dis-
tinct PubMed articles and 11,125 distinct genes. This represents
44.5% of the 25,000 genes roughly estimated to exist currently.
Of 25,000 genes, we are able to annotate 7316 (29.2%) with at least
one disease concept from the DO.Table 1
The following table lists the top disease terms associated with aging-rel
as determined by medical experts; meaning that these terms are disea
Note that mis-annotated terms (such as Recruitment) and non-inform
analysis, as expected.
Term Frequency
DNA damage 53
Alzheimer’s disease 20
Recruitment 18
Atherosclerosis 13
Fibroepithelial neoplasm 10
Disease 9
Insulin resistance 7
Ataxia 6
Cockayne syndrome 6
Dependence 6
Burkitt’s tumor or lymphoma 4
Dwarﬁsm 2
Fig. 3. Aging-related diseases: Using the 261 human genes identiﬁed in the GenAge datab
the tag cloud displays more frequently appearing terms using larger font sizes.3.1. Recapitulating known disease associations
On examining the automatically assigned disease annotations
for a well-known gene such as TP53, we found that TP53 was anno-
tated to DNA Damage 25 times based on 25 different abstracts, to
cancer 16 times, ﬁbroepithelial neoplasm nine times and was also
annotated with speciﬁc diseases such as colorectal cancer and
Li-Fraumeni syndrome. TP53 was also annotated, wrongly, to
Recruitment four times. We discuss such mis-annotations and their
effect on the enrichment analysis later in the paper. Similarly,
BRCA1 was annotated with hereditary breast ovarian cancer 45
times,malignant neoplasm of breast 20 times, DNA damage 20 times,
malignant neoplasm of ovary eight times and retinoblastoma two
times (BRCA1 is known to bind the RB1, retinoblastoma 1, protein).3.2. Summary of annotations of known aging genes
We used a set of 261 human genes known to be associated with
aging, as provided by the GenAge database. For this subset, we
pulled out the gene-disease associations from our automatically
created disease annotation dataset. We were able to create annota-
tions for 236 (91%) of the known aging genes in humans. By aggre-
gating the number of genes per disease concept, we obtained
frequencies for the top disease concepts listed in Table 1.
As we can see in Fig. 3, the concepts that annotate multiple
genes in this aging-related gene set make biological sense. For
example, DNA Damage is known to occur with aging. Alzheimer’s
disease and Atherosclerosis are also known to increase with age.
There is also an obvious mis-annotation – Recruitment; this term
is in the DO and is a synonym of auditory recruitment (DOID:12659)
but does not have an asserted superclass, indicating a possible
error in the ontology.ated genes. Most of the enriched terms are biologically meaningful
ses or conditions that are understood to be associated with aging.
ative terms (such as Disease) are not deemed enriched by the
Enriched? p-values
Yes 0.00002429743370435670
Yes 0.00210785976415961000
0.99999999719663000000
Yes 0.00269862200185977000
1.00000000000000000000
1.00000000000000000000
Yes 0.01181595036983900000
0.36411632694226000000
Yes 0.00480121896261565000
0.73713523946908800000
Yes 0.00975066042777684000
Yes 0.00923404669915151000
ase and the gene-disease linkages discovered during the workﬂow we have deﬁned,
Fig. 4. Disease terms signiﬁcantly enriched in annotations of aging-related genes: This tag cloud shows those disease terms in the annotations of the 261 aging-related genes
that are statistically enriched given our gene-disease background annotation set. Terms that are signiﬁcantly enriched appear larger.
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As a further validation of the utility of our background annota-
tion set, we identiﬁed disease concepts that are statistically
enriched – in the annotations of the 261 aging-related genes –
given our gene-disease background annotation dataset. As
mentioned in our methods, we used a binomial test to detect
enriched disease concepts in the aging-related gene set. Whether
a particular concept is enriched or not is shown in Table 1 (enrich-
ment column) and Fig. 4 provides a tag-cloud visual. Note that
mis-annotated terms (such as Recruitment) and non-informative
concepts (such as Disease) are not deemed enriched in the statisti-
cal analysis.
On examining the disease concepts found enriched, we found
that in most cases the disease assigned to the aging gene was
conﬁrmed by a literature search. For example, Cockayne syndrome,
Burkitt’s lymphoma, Spastic Paraparesis and Rothmund–Thomson
Syndrome are all speciﬁcally linked to the underlying gene that
GeneAge declared as aging-related (and hence was in our set of
261 genes). In fact the relationship between accelerated aging
syndromes (such as Rothmund–Thomson Syndrome) and natural
aging is an emerging research area [6–9].4. Discussion
From our results, the use of human curated annotations as a
starting point for generating automated annotations using other
ontologies seems promising-annotating 29.2% of genes. Previous
methods that use advanced text mining have been able to annotate
4408 genes (17.7%) [21]. A study based on OMIM associated 1777genes (7.1%) with diseases to create a human ‘‘diseasome’’ [22].
Based on a similar assumption that curated annotations will yield
better results, Osborne et al. annotate GeneRIF descriptions to infer
disease relationships to 5376 genes (21.5%) [16]. Because the num-
ber of human genes known at the time of these studies varies, we
make the comparisons loosely.
However, there are some caveats to consider. First, not all ontol-
ogies are equally suited for creating automated annotations.
Second, automated annotation depends highly on the quality of
the text corpus. We discuss these issues below.4.1. Using other ontologies
The Human Disease Ontology is a community-driven, open
source ontology designed speciﬁcally to link disparate datasets
through disease concepts under the principles of the Open Bio-
medical Ontologies Foundry. Osborne et al. note that the DO pro-
vides several advantages including good disease coverage and a
useful hierarchical structure for mapping disease terms to a large
text corpus [16]. For the purpose of the current discussion, and
enrichment analysis in general, just about any disease ontology
that provides a clear hierarchy of parent–child for diseases
would be suitable for use—e.g., SNOMED CT, the National Cancer
Institute thesaurus (NCIt), the International Classiﬁcation of Dis-
eases (ICD)—insofar as their vocabularies work well for entity
extraction (see below). For concepts that are linked together
(as in the UMLS Metathesaurus), the additional synonyms ob-
tained from related concepts can be incorporated to expand
the coverage of the concept recognition system. This feature,
which is only partially available in the form of the Annotator
Table 2
The 24 (out of 261 aging-related) genes and gene products that were not associated with a disease term.
UniProt ID Recommended name Gene name
O00327 Aryl hydrocarbon receptor nuclear translocator-like protein 1 ARNTL
O15120 1-acyl-sn-glycerol-3-phosphate acyltransferase beta AGPAT2
O15217 Glutathione S-transferase A4 GSTA4
O15243 Leptin receptor gene-related protein LEPROT
O15516 Circadian locomoter output cycles protein kaput CLOCK
O75844 CAAX prenyl protease 1 homolog ZMPSTE24
O95985 DNA topoisomerase 3-beta-1 TOP3B
P00390 Glutathione reductase, mitochondrial GSR
P00395 Cytochrome c oxidase subunit 1 MT-CO1
P09629 Homeobox protein Hox-B7 HOXB7
P13639 Elongation factor 2 EEF2
P20382 Pro-MCH PMCH
P25874 Mitochondrial brown fat uncoupling protein 1 UCP1
P32745 Somatostatin receptor type 3 SSTR3
P36969 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial GPX4
P61278 Somatostatin SST
P62987 Ubiquitin-60S ribosomal protein L40 UBA52
P78406 mRNA export factor RAE1
P98177 Forkhead box protein O4 FOXO4
Q00613 Heat shock factor protein 1 HSF1
Q13219 Pappalysin-1 PAPPA
Q99643 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial SDHC
Q99807 Ubiquinone biosynthesis protein COQ7 homolog COQ7
Q9UBI1 COMM domain-containing protein 3 COMMD3
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but the effort is not complete yet.
Although we speciﬁcally focus on creating annotations with dis-
ease terminology, the method we have devised (Fig. 1) can create
annotations with terms from any ontology. In our workﬂow, to ob-
tain a background dataset for enrichment analysis using some
ontology other than the DO, researchers would simply conﬁgure
a parameter for the NCBO Annotator to use their ontology of choice
from BioPortal. In fact, other researchers have used a similar anno-
tation workﬂow to recognize morphological features in textual
descriptions of ﬁsh species [24]. Moreover, researchers can use
the annotation tool of choice (e.g., MetaMap).
However, not all ontologies are viable candidates for automatic
annotation because the vocabulary used in texts is not always
reﬂective of that in ontologies. For example, using term-frequency
counts—for all terms from BioPortal ontologies—in MEDLINE ab-
stracts [25], we calculated that disease terms are mentioned 46%
more often than GO terms in MEDLINE abstracts. As another exam-
ple, on comparing NCBO Annotator results using the GO to auto-
matically annotate genes based on the PubMed articles provided
as the basis of the GO annotation, we ﬁnd that only 10% of the cu-
rated GO annotations can be detected directly in the paper abstract
supporting a particular GO annotation.
Because disease terms are mentioned signiﬁcantly more often
than GO terms, the automated annotation process works better
for annotating genes with disease ontology terms than it would
for performing automatic GO annotation. Starting with curated
gene-publication annotations ensures high accuracy.
4.2. Missing annotations
Out of the 261 aging-related genes in our evaluation subset, the
NCBO Annotator left-out 24 genes (9%). Therefore, we have no dis-
ease terms associated with those genes in our gene-disease associ-
ation dataset. The 24 genes (mentioned as UniProt IDs) that were
not associated to a disease term are listed in Table 2. These missed5 h t t p : / /www .b i o on t o l o g y . o r g /w i k i / i n d e x . php /Anno t a t o r _U s e r _
Guide#The_mapping_expansion_componentannotations provide an opportunity for reﬁning the annotation
workﬂow to use sources beyond just the papers referenced in GO
annotations, e.g., GeneRIF references.4.3. Dealing with annotation errors
Some errors in annotation are inevitable in an automated pro-
cess. For example, in the reference annotation set we created,
TP53 was also annotated, wrongly, to Recruitment. Papers that
were the basis of creating GO annotations for TP53 certainly men-
tion the term Recruitment, however, that term is not a disease. De-
spite these kinds of errors, because they affect annotation of both
the set of interest and the reference set equally, the errors will
most likely cancel each other out when computing statistical
enrichment (Fig. 4)—though that is not guaranteed. We can deal
with such errors in a variety of ways. For example, we can add a list
of terms that commonly lead to errors to our set of stop words (i.e.,
terms to ignore). We can also use more advanced text mining tech-
niques to analyze the context in which a potential disease term is
mentioned using MEDLINE term frequencies and part-of-speech
tags [25] to detect false positives. The accuracy of the NCBO Anno-
tator in recognizing disease names has been evaluated in prior
work [17]. A repeat study of the sensitivity and speciﬁcity (or recall
and precision) of the NCBO Annotator is outside the scope of this
work.4.4. Future work
Text mining can potentially provide checks against possible hu-
man errors. The Recruitment mis-annotation is one case in point.
Additionally, for questionably enriched diseases, such as Septo-op-
tic dysplasia (a developmental disorder believed to be linked to an
aging gene), we plan to performmore thorough, manual validation.
We would use the approach of review by two or more experts and
a protocol for resolving disagreement, and we plan to do this work
speciﬁcally in the context of disease enrichment in electronic pa-
tient records.
Fig. 5. Disease terms signiﬁcantly enriched in annotations of patient reports coded with ICD9 789.00 (Abdominal pain, unspeciﬁed), one of the top reasons for patients being
admitted to emergency rooms. Patient reports were obtained from the University of Pittsburg NLP Repository (http://www.dbmi.pitt.edu/blulab/nlprepository.html) with IRB
approval.
P. LePendu et al. / Journal of Biomedical Informatics 44 (2011) S31–S38 S37We acknowledge the fact that publications might mention ne-
gated ﬁndings. For this reason, we exclude the publications that
were the basis of a negated GO annotation (i.e., qualiﬁed with
NOT). Having negation detection functionality can certainly affect
the outcome of enrichment analysis by altering the reference term
frequencies. For this study, negations were not considered, but we
have subsequently implemented the NegEx algorithm [26] within
the framework of the Annotator and we are currently testing nega-
tion detection within the context of electronic health records.
Finally, we relied upon GO annotations to provide one reliable
source for gene-publication associations. Likewise, GeneRIF
descriptions and their referenced PubMed articles could offer an-
other source of similar information. Compared to the 44,103 arti-
cles obtained from GO annotations in our case study, GeneRIF
entries for homo sapiens reference a much larger corpus of
208,4066 distinct PubMed articles. Other possible sources could in-
clude the CALBC7 corpus, or Entrez eLink8 publications. We have
subsequently used GeneRIFs for ﬁnding gene-disease associations
and are currently thinking of ways to compare the results with those
from PubMed.
Although we demonstrate the beneﬁts of enrichment analysis
with ontologies other than the GO (especially those for which a ref-
erence annotation set does not exist) within the context of its most6 http://www.ncbi.nlm.nih.gov/projects/GeneRIF/stats/
7 http://www.calbc.eu/
8 http://www.ncbi.nlm.nih.gov/corehtml/query/static/elink_help.htmlpopular use (gene expression proﬁling), the method is general en-
ough to beneﬁt a host of other applications as well, such as proﬁl-
ing patient reports. For example, one of the most common reasons
patients are admitted to the emergency room is for abdominal
pain, which is often coded with ICD9 789.00 (Abdominal pain,
unspeciﬁed). We can designate our set of interest as all patients
coded with 789.00 and compare them against all patients on re-
cord using enrichment analysis over their clinical notes, to obtain
a proﬁle of this cohort (Fig. 5). We can use DO to obtain a disease
proﬁle, or we can use RxNorm to obtain a drug proﬁle, and so on.
We have subsequently obtained access to Stanford’s entire clinical
data warehouse, and have annotated over 9.5 million patient re-
ports with 15 different ontologies. We are currently in the process
of analyzing the results, which will include enrichment analysis
along not only diseases and ﬁndings, but also along drugs and ad-
verse events. The main challenge will be to develop methods of
analyzing these aspects in combination.5. Conclusion
Enrichment analysis using GO annotations is widely used to
make sense of the results of high-throughput experiments. Our
goal is to generalize enrichment analysis methods to use a variety
of ontologies including SNOMED CT, Human Disease Ontology, and
others. With the availability of automated ontology-based annota-
tion with terms from biomedical ontologies, it is possible to
S38 P. LePendu et al. / Journal of Biomedical Informatics 44 (2011) S31–S38perform enrichment analysis using ontologies other than the Gene
Ontology. However, a key pre-requisite for such analysis is the
availability of a background set of annotations to enable the
enrichment calculation.
We have described a general method, which uses hand-curated
GO annotations as a starting point, for creating background data-
sets for enrichment analysis using other ontologies—such as the
Human Disease Ontology, for which hand-curated annotations
are not available.
To demonstrate the feasibility and utility of our method, we
have created a background set of annotations to enable enrichment
analysis with the DO and validated that background set by using
the created annotations to examine the coherence of known
aging-related genes and by performing enrichment analysis on
an aging-related gene set from the GeneAge database [23]. In fu-
ture work, we plan to apply enrichment analysis methods to ana-
lyze patient cohorts from electronic health records.
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